Spatiotemporal Characterization of GSTO1 Inhibition in Postoperative Cognitive Dysfunction: Roles of Hippocampal Oxidative Stress and Neuroinflammation in Aged Mice

As the global population ages, more elderly people are undergoing major surgeries to treat serious conditions. While these operations often save lives, they sometimes come with a hidden cost: a decline in mental sharpness after the procedure. This condition, known as postoperative cognitive dysfunction, can leave patients struggling with memory, focus, and the ability to think clearly. Scientists have long suspected that the brain's internal environment becomes unstable during and after surgery, specifically due to a buildup of harmful molecules called reactive oxygen species and a surge in inflammation. These factors act like rust and fire inside the brain, damaging the delicate cells responsible for learning and memory. To understand how this damage happens, researchers are looking for the body's natural defense mechanisms that usually keep these harmful forces in check. One such defender is an enzyme called GSTO1, a protein found in high concentrations in the hippocampus, the brain's primary center for forming new memories. This protein acts as a cleanup crew, neutralizing toxic byproducts and keeping the brain's chemical balance steady.

A new study published by researchers in China investigates what happens when this specific defense system is weakened in older mice. The team wanted to see if lowering the levels of GSTO1, combined with the stress of surgery, would accelerate memory loss. They focused on the timeline of events, tracking changes in the brain at six hours, three days, and seven days after the intervention. By using a specific chemical to temporarily block the activity of GSTO1 in the hippocampus, they could observe how the brain's internal environment unraveled over time. The goal was not just to see if memory failed, but to map the exact sequence of chemical and structural changes that led to that failure. This approach helps clarify whether the loss of this protective protein is a direct cause of the confusion seen in elderly patients after surgery, or merely a side effect.

The researchers began by preparing seventy-two older mice for the experiment. They divided the animals into four groups to isolate the effects of surgery, the chemical blocker, and the combination of both. One group underwent a standard exploratory surgery on the abdomen, which is known to cause physical stress, while another group received only anesthesia and a small incision to serve as a control. Within the surgical groups, some mice received a harmless liquid injection into the brain, while others received the specific chemical inhibitor designed to block GSTO1. Before any procedures began, all the mice were trained to find a hidden platform in a large pool of water, a test that measures their ability to remember locations. This ensured that every mouse started with the same level of memory capability. The researchers were careful to ensure that every mouse received the exact same amount of anesthesia and that their body temperatures remained stable, removing any variables that could skew the results.

Once the interventions were complete, the team watched how the mice performed over the next week. At the six-hour mark, the mice that had received the chemical blocker showed a sharp drop in the levels of GSTO1 in their brains. This immediate loss of protection triggered a rapid chemical imbalance. The natural antioxidants that usually keep the brain safe were depleted, while harmful oxidative molecules began to accumulate. This state of chemical distress did not stay contained; by the third and seventh days, the brain's immune system had kicked into overdrive. The researchers detected a significant rise in inflammatory signals, specifically a protein called TNF-alpha, which is a marker of the brain's immune response to injury. This inflammation grew stronger over time, creating a hostile environment for the brain cells.

The physical consequences of this chemical and inflammatory storm became visible in the brain's structure. The researchers examined the hippocampus and found that the harmful effects were not uniform across the entire region. In the dentate gyrus and the CA3 area, which are critical for forming new memories, the accumulation of a damaging protein called amyloid precursor protein began as early as six hours after the intervention. In contrast, the CA1 region showed signs of this damage later, appearing clearly only by the third and seventh days. This difference suggests that some parts of the memory center are more vulnerable to this type of stress than others. The mice that had both the surgery and the chemical blocker showed the most severe damage, with the highest levels of inflammation and protein accumulation.

The behavioral tests confirmed that these internal changes had real-world consequences. When the mice were tested again three and seven days after the procedure, those that had undergone surgery and received the GSTO1 blocker struggled significantly to remember the location of the hidden platform. They took longer to find it and swam less directly toward the target area compared to the other groups. Even the mice that received only the chemical blocker, without surgery, showed mild memory problems, proving that suppressing this protective enzyme is harmful on its own. However, the combination of surgery and the blocker caused the most severe decline, indicating that the stress of an operation makes the brain much more dependent on GSTO1 to stay healthy. The study suggests that when this defense system is compromised, the brain cannot recover from the oxidative stress and inflammation caused by surgery, leading to lasting memory deficits.

The researchers also took great care to ensure that the chemical they used was effective and safe. They tested different concentrations to find the precise amount needed to block the enzyme in the brain without causing physical harm or affecting the mice's ability to swim. They found that the amount required to work inside the living brain was much higher than what is needed in a test tube, a common challenge when delivering drugs to the brain. Once they settled on the correct dose, they confirmed that it did not damage the brain tissue or alter the mice's basic movement. This precision allowed them to be confident that the memory problems they observed were specifically due to the loss of GSTO1 function, not a side effect of the drug itself.

This work provides a detailed map of how a specific molecular failure can lead to cognitive decline in the elderly. It shows that the loss of GSTO1 sets off a chain reaction: first, the brain's chemical balance is disrupted; second, inflammation takes hold; and third, structural damage begins to accumulate in specific memory centers. The study highlights that the timing of these events matters, with some parts of the brain reacting faster than others. While the researchers note that their findings are based on animal models and that further studies are needed to confirm if the same process happens in humans, the results offer a clear explanation for why some older patients struggle with memory after surgery. It suggests that protecting or restoring this specific enzyme could be a key strategy for preventing cognitive decline in the future, offering a potential target for new treatments to help the aging brain withstand the stress of medical procedures.